Page last updated: 2024-11-13

pyrithiobac sodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23682187
CHEMBL ID3186632
CHEBI ID81973
SCHEMBL ID1526066
MeSH IDM0354097

Synonyms (50)

Synonym
pyrithiobac sodium
sodium 2-chloro-6-(4,6-dimethoxypyrimidin-2-ylthio)benzoate
kih 2031
benzoic acid, 2-chloro-6-((4,6-dimethoxy-2-pyrimidinyl)thio)-, sodiu, salt
staple 85sp
dpx-pe 350
sodium 2-chloro-6-((4,6-dimethoxy-2-pyrimidinyl)thio0benzoate
staple
pyrithiobac-sodium [iso]
pyrithiobac-sodium
sodium 2-chloro-6-[(4,6-dimethoxypyrimidin-2-yl)thio]benzoate
123343-16-8
sodium 2-chloro-6-[(4,6-dimethoxy-2-pyrimidinyl)thio]benzoate
A805059
sodium 2-chloranyl-6-(4,6-dimethoxypyrimidin-2-yl)sulfanyl-benzoate
C18805
cas-123343-16-8
tox21_300849
dtxsid8032673 ,
NCGC00254752-01
dtxcid6012673
benzoic acid, 2-chloro-6-((4,6-dimethoxy-2-pyrimidinyl)thio)-, sodium salt
unii-5m13luj9wy
5m13luj9wy ,
AKOS015963552
FT-0631114
AM20020319
benzoic acid, 2-chloro-6-[(4,6-dimethoxy-2-pyrimidinyl)thio]-, sodium salt (1:1)
AKOS015888795
pyrithiobac sodium salt [mi]
kih-2031
benzoic acid, 2-chloro-6-((4,6-dimethoxy-2-pyrimidinyl)thio)-, sodium salt (1:1)
pyrithiobac sodium salt
dpx-pe350
staple-85sp
CHEBI:81973 ,
CNILNQMBAHKMFS-UHFFFAOYSA-M
SCHEMBL1526066
AC-27683
pyrithiobac-na
CHEMBL3186632
AS-73720
sodium 2-chloro-6-[(4,6-dimethoxypyrimidin-2-yl)sulfanyl]benzoate
D94454
mfcd13194969
2-chloro-6-{(4,6-dimethoxy-2-pyrimidinyl)thio}benzoic acid sodium salt
Q27155670
sodium;2-chloro-6-(4,6-dimethoxypyrimidin-2-yl)sulfanylbenzoate
pyrithiobac sodium 100 microg/ml in acetonitrile
CS-0150452
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.73520.000229.305416,493.5996AID743075; AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (22.22)18.2507
2000's2 (22.22)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.22 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index78.27 (26.88)
Search Engine Supply Index2.73 (0.95)

This Compound (42.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]